BioNano Genomics Inc vs JPMorgan Ultra Short Income ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: JPMorgan Ultra Short Income ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | JPST | |
|---|---|---|
Market Cap | $13.66M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.92 | $50.78 |
52-Week Low | $1.06 | $50.40 |
Enterprise Value | $16.26M | — |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
JPST (JPMorgan Ultra-Short Income ETF) trades at $50.46, showing minimal daily movement with a 0.04% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent institutional filings show growing interest, with Financial Management Professionals increasing their stake by 4.7% in Q2 2026. The fund provides regular dividend distributions, with recent payments of $0.17 per share.
As an ultra-short income ETF, JPST offers stability and income generation in a rising rate environment. The fund's conservative positioning appeals to risk-averse investors seeking cash alternatives. Key risks include interest rate sensitivity and inflationary pressures that could impact short-term bond yields. Institutional accumulation suggests confidence in the fund's strategic positioning.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →